Free tool
FAERS Monitor: Crysvita
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761068 or its brand name (Crysvita, Burosumab-Twza). Reports on generic versions are filed under their own applications.
Reports
6,487
Serious
1,394
21% of reports
Hospitalization
481
Death reported
43
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- inappropriate schedule of product administration719
- product dose omission issue677
- blood phosphorus decreased584
- pain408
- arthralgia385
- pain in extremity364
- restless legs syndrome284
- headache282
- fatigue260
- incorrect dose administered258
- injection site pain246
- bone pain216
- back pain194
- contraindicated product administered192
- pyrexia185
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 117 |
| 2019 | 801 |
| 2020 | 1,134 |
| 2021 | 1,266 |
| 2022 | 1,336 |
| 2023 | 417 |
| 2024 | 454 |
| 2025 | 493 |
| 2026 | 469 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood phosphorus decreasedSignal | 584 | 616.2 | 566.0 | 300,984 |
| restless legs syndromeSignal | 284 | 51.4 | 45.9 | 13,786 |
| contraindicated product administeredSignal | 192 | 20.7 | 18.0 | 3,560 |
| inappropriate schedule of product administrationSignal | 719 | 13.0 | 12.1 | 7,977 |
| bone painSignal | 216 | 12.0 | 10.5 | 2,164 |
| product dose omission issueSignal | 677 | 7.5 | 7.0 | 3,839 |
| pain in extremitySignal | 364 | 4.0 | 3.6 | 830 |
| incorrect dose administeredSignal | 258 | 3.7 | 3.3 | 503 |
| arthralgiaSignal | 385 | 3.0 | 2.7 | 523 |
| back painSignal | 194 | 2.7 | 2.4 | 210 |
| injection site painSignal | 246 | 2.6 | 2.3 | 244 |
| painSignal | 408 | 2.2 | 2.0 | 259 |
| pyrexia | 185 | 1.7 | 1.5 | 58 |
| headache | 282 | 1.5 | 1.3 | 41 |
| fatigue | 260 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.